Research & Development: Page 28
-
Profile
Jumping into pharma with big plans at a small company
SpringWorks Therapeutics' chief medical officer on the ambition that drives him and his company to develop treatments for cancer patients.
By Alexandra Pecci • May 17, 2022 -
Q&A
BriOri BioTech sets the stage for the comeback of Vioxx
With a topical pain-relieving ointment in development, the emerging biotech is aiming to give the tarnished NSAID a new life.
By Kelly Bilodeau • May 17, 2022 -
Explore the Trendline➔
Stock via Getty ImagesTrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
Q&A // Biotech Spotlight
Biotech Spotlight: Graphite Bio seeks sickle cell cure with a next-gen approach
Using gene editing, CEO Josh Lehrer says the company is poised to ‘offer a cure’ to a long list of diseases.
By Michael Gibney • May 17, 2022 -
Are digital DCTs the answer for rare diseases?
How data from EHRs is helping to identify, diagnose and recruit patients to decentralized clinical trials.
By Kim Ribbink • May 16, 2022 -
After 40 years, researchers discover new frontiers in the fight against HIV
Medical advances in the last two decades may now provide scientists with the right toolbox to target the long-elusive virus.
By Karissa Waddick • May 16, 2022 -
Profile
With the shine of amyloid fading, tau is a rising star in Alzheimer's
The tau theory in Alzheimer's is being put to the test with phase 3 trial results due later this month from TauRx Pharmaceuticals.
By Michael Gibney • May 11, 2022 -
In the hot pharma talent market, execs battle these recruitment misconceptions
One of the top recruiting firms in life sciences weighs in on how companies can attract the next wave of rising stars.
By Meagan Parrish • May 11, 2022 -
FDA draft guidance may turn diversity in clinical trials from nice-to-have into a must-have
New guidance from the FDA will ‘up the ante’ for diversity considerations. Here’s how your company can prepare.
By Kelly Bilodeau • May 10, 2022 -
Where hope and uncertainty meet: A cutting-edge cancer developer's winding road
Replimune is on the precipice of a new kind of cancer treatment, but its CEO knows something about ambiguity.
By Alexandra Pecci • May 9, 2022 -
Q&A // Biotech Spotlight
Biotech Spotlight: Everest Medicines takes aim at unmet needs in Asia
With a multi-pronged business strategy, Everest Medicines is positioning itself as a ‘rising force’ in Asian biotech.
By Taren Grom • May 9, 2022 -
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
Ultra-sensitive tests bring biomarkers into the drug development forefront
An agreement between the biomarker assay maker Quanterix and pharma giant Eli Lilly could help discover new ways to treat Alzheimer's.
By Michael Gibney • May 5, 2022 -
Podcast
Woman of the Week: Amgen's Dr. Jane Parnes
As executive medical director, early development at Amgen, Dr. Jane Parnes has helped guide clinical research for upwards of 30 of the company’s investigational molecules, including the newly approved Tezspire for severe asthma — one of her career highlights.
By Taren Grom • May 4, 2022 -
Profile
Breaking new ground: Longhorn's trailblazing effort to develop a universal flu vaccine
After years of success with their diagnostic platform for COVID-19, tuberculosis and the flu, the family funded company is shifting priorities back to the vaccine market.
By Taren Grom , Karissa Waddick • May 4, 2022 -
Profile
From cancer survivor to clinical trial innovator
How Alicia Staley is using her insights as a three-time cancer survivor to drive clinical trial improvements at Medidata.
By Kelly Bilodeau • May 3, 2022 -
Q&A
One company's failed drug is this company's 'jewel'
Dr. Thomas Bock, CEO of Notable, is helping the company develop a ‘new class’ of predictive precision medicines in oncology.
By Meagan Parrish • May 2, 2022 -
A nuclear threat spurs France's Medesis to advance radiation therapy
In the event of a nuclear event — intentional or accidental — rapid and widespread deployment of effective treatments is paramount.
By Kelly Bilodeau • May 2, 2022 -
Q&A
How an open platform can shake up the drug development process
TetraScience’s Alan Millar shares why pharma is rethinking data integration in the race to be faster, better and more effective.
By Kim Ribbink • April 28, 2022 -
Podcast
Woman of the Week: Gilead Science's Dr. Shanthi Ganeshan
As vice president of Global Regulatory Affairs, Oncology at Gilead, Ganeshan says there’s ‘never a dull moment’ in the quest to deliver therapies to patients.
By Taren Grom • April 27, 2022 -
Profile
Laura Randa's aim to break down mental healthcare barriers for disabled patients
Despite the proliferation of mental health apps, many aren’t accessible for people with disabilities. The CEO of Toivoa plans to change that.
By Alexandra Pecci • April 27, 2022 -
Q&A
Real-world data is making drug development more true to life
How RWD is moving from the background to the spotlight in pharma’s development process.
By Kelly Bilodeau • April 26, 2022 -
Profile
Mouse vs. machine: Using AI to solve the animal testing model in pharma
Quris is bringing its first drug tested preclinically using AI — rather than animal models — into human trials.
By Michael Gibney • April 26, 2022 -
Q&A // Biotech Spotlight
How OliX Pharmaceuticals is riding the RNAi wave
While the company may look like “the new kid on the block,” CEO Dong-ki Lee says the Korean biotech is ready for the global stage.
By Karissa Waddick , Taren Grom • April 25, 2022 -
From the fringes to the forefront — the mRNA era has taken hold of pharma
A look at what’s next for the industry’s buzziest technology.
By Kim Ribbink • April 22, 2022 -
Q&A
The cannabis vanguard: A rare disease company looks to pioneer in the space
Zynerba’s CEO shares his views on advances in cannabidiol treatments for neuropsychiatric illnesses and the regulatory environment for CBD-based drugs.
By Jared Whitlock • April 21, 2022 -
Q&A
A psychedelic pill for alcoholism? The CEO of Clearmind Medicine says 'Yes.'
Known to provide a “euphoric” experience, MEAI started out as a recreational drug used as an alcohol substitute. Now, Adi Zuloff-Shani says it may even treat alcohol addiction.
By Alexandra Pecci • April 21, 2022